Continuous glucose monitoring reveals bimodal glycemic patterns during and outside Capivasertib administration

ABSTRACT Capivasertib, an AKT inhibitor, interferes with insulin signaling and can induce hyperglycemia. In this case, we monitored blood glucose fluctuations using continuous glucose monitoring (CGM) during capivasertib administration. During the administration period, a post‐dose increase in blood...

Whakaahuatanga katoa

Ngā taipitopito rārangi puna kōrero

Ngā kaituhi matua:	Yuya Suzuki, Takeshi Yamaguchi, Takayasu Uchida, Kimio Matsumura, Nozomi Harai, Kaoru Nagasawa, Yuko Tanabe, Koichi Suyama, Takashi Kadowaki, Yasumichi Mori
Hōputu:	Artigo
Reo:	Inglês
I whakaputaina:	Wiley 2026-04-01
Rangatū:	Journal of Diabetes Investigation
Ngā marau:	Capivasertib Continuous glucose monitoring Hyperglycemia
Urunga tuihono:	https://doi.org/10.1111/jdi.70261
Ngā Tūtohu:	Tāpirihia he Tūtohu Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!